[1] 庹吉妤, 张敏, 郑荣寿, 等. 2015 年中国恶性淋巴瘤发病与死亡分析[J]. 中国肿瘤,2021, 30(1): 35-40. Tuo JY, Zhang M, Zheng RS, et al.Analysis of malignant lymphoma incidence and mortality in China, 2015[J]. China Cancer, 2021, 30(1): 35-40. [2] Barone S, Buffone C, Ferrillo M, et al.Oral malignant non-Hodgkin lymphoma: a retrospective single-center study[J]. Int J Environ Res Public Health, 2022, 19(5): 2605. [3] Swerdlow SH, Campo E, Pileri SA, et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. [4] Shankland KR, Armitage JO, Hancock BW.Non-Hodgkin lymphoma[J]. Lancet, 2012, 380(9844): 848-857. [5] Walter C, Ziebart T, Sagheb K, et al.Malignant lymphomas in the head and neck region-a retrospective, single-center study over 41 years[J]. Int J Med Sci, 2015, 12(2): 141-145. [6] Zapater E, Bagán JV, Carbonell F, et al.Malignant lymphoma of the head and neck[J]. Oral Dis, 2010, 16(2): 119-128. [7] Hart S, Horsman JM, Radstone CR, et al.Localised extranodal lymphoma of the head and neck: the Sheffield Lymphoma Group experience (1971-2000)[J]. Clin Oncol, 2004, 16(3): 186-192. [8] Ezzat AA, Ibrahim EM, El Weshi AN, et al.Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients[J]. Head Neck, 2001, 23(7): 547-558. [9] Singh R, Shaik S, Negi BS, et al.Non-Hodgkin's lymphoma: a review[J]. J Fam Med Prim Care, 2020, 9(4): 1834-1840. [10] Abdelwahed Hussein MR.Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint[J]. Expert Rev Hematol, 2018, 11(9): 737-748. [11] Bhattacharyya I, Chehal HK, Cohen DM, et al.Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification[J]. Head Neck Pathol, 2010, 4(3): 181-191. [12] Poeschel V, Held G, Ziepert M, et al.Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial[J]. Lancet, 2019, 394(10216): 2271-2281. [13] International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma[J]. N Engl J Med, 1993, 329(14): 987-994. [14] 朱海燕, 李菲, 赵瑜, 等. 组合临床国际预后指数、病理免疫分型及中期PET/CT建立的模型在弥漫大B细胞淋巴瘤预后评估中的应用[J]. 中国医学影像学杂志, 2019, 27(4): 298-301, 308. [15] Harlendea NJ, Harlendo K.Ki-67 as a marker to differentiate Burkitt lymphoma and diffuse large B-cell lymphoma: a literature review[J]. Cureus, 2024, 16(10): e72190. |